CYCN · As filed with the SEC
Korsana Biosciences income statement, by quarter
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q4 2024 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Revenues: | ||||||
| Total revenues | — | 0 | — | 875,000 | 93,000 | — |
| Revenue from purchase agreement | — | — | — | 800,000 | — | — |
| Revenue from option agreement | — | 0 | — | 75,000 | 93,000 | — |
| Cost and expenses: | ||||||
| Research and development | — | 730,000 | — | 348,000 | 56,000 | — |
| General and administrative | 1,771,000 | 2,479,000 | — | 1,533,000 | 1,709,000 | — |
| Total cost and expenses | 1,771,000 | 3,209,000 | — | 1,881,000 | 1,765,000 | — |
| Loss from operations | (1,771,000) | (3,209,000) | — | (1,006,000) | (1,672,000) | — |
| Other income, net | ||||||
| Interest income | 16,000 | 32,000 | — | 30,000 | 31,000 | — |
| Gain from settlement of account payable | — | — | — | 0 | — | — |
| Gain from insurance recovery | — | — | — | 0 | 1,317,000 | — |
| Net loss | — | — | — | (976,000) | (324,000) | — |
| Total other income, net | 16,000 | 32,000 | — | 30,000 | 1,348,000 | — |
| Net loss and other comprehensive loss | (1,755,000) | (3,177,000) | — | — | — | — |
| Net loss per share: | ||||||
| Basic net loss per share | (0.41) | (0.76) | — | (0.3) | (0.11) | — |
| Diluted net loss per share | (0.41) | (0.76) | — | (0.3) | (0.11) | — |
| Weighted average shares used in calculating: | ||||||
| Basic shares | 4,251,000 | 4,205,000 | — | 3,225,000 | 3,071,000 | — |
| Diluted shares | 4,251,000 | 4,205,000 | — | 3,225,000 | 3,071,000 | — |
| Net loss | — | — | — | (976,000) | (324,000) | — |
| Foreign currency translation adjustment loss | — | — | — | 0 | 0 | — |
| Comprehensive loss | — | — | — | (976,000) | (324,000) | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.